Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab.

NPJ Breast Cancer · 2021 · PMC8196206 · PMID 34117262

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

borderline significantP = 0.052so close (0.05 < p ≤ 0.1)

The breast tumor pCR rate increased by 9.2% when exposed to dose-dense chemotherapy, with a borderline significant difference compared with patients exposed to standard-interval chemotherapy ( P = 0.052).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.